Mash | List of Frontiers open access articles

Brief Research Report

Published on 20 Aug 2024

Sexual dimorphism in hepatic PPAR alpha and CYP4a12a expression is associated with reduced development of drug-induced non-alcoholic steatohepatitis in female IL-33−/− mice

in Hepatobiliary Diseases

Chloe Thomas
Dolores B. Njoku

Frontiers in Medicine

doi 10.3389/fmed.2024.1425528

2,835 views
1 citation

Original Research

Published on 23 Jan 2026

EMMPRIN deficiency alleviated metabolic-associated steatohepatitis progression via regulation of the UBA52–MCT1 axis

in Gastrointestinal and Hepatic Pharmacology

Linying Lai
Baoyuan Huang
Ziping Song
Xinyan Zhu
Wenzhuo Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1706859

628 views

Original Research

Published on 16 May 2024

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

in Inflammation

Sturla Magnus Grøndal
Anna Tutusaus
Loreto Boix
Maria Reig
Magnus Blø
Linn Hodneland
Gro Gausdal
Akil Jackson
Pablo Garcia de Frutos
James Bradley Lorens

Frontiers in Immunology

doi 10.3389/fimmu.2024.1400553

10,616 views
13 citations

Original Research

Published on 04 Nov 2024

Common molecular basis for MASH and hepatitis C revealed via systems biology approach

in Cancer Immunity and Immunotherapy

Yongwei Cheng
Zihao Song
Ye Liu
Xichao Xu
Dali Zhang
Yigui Zou
Liang Liu
Yinzhen Zeng
Wenwen Li
Daming Bai

Frontiers in Oncology

doi 10.3389/fonc.2024.1442221

4,017 views

Original Research

Published on 21 Oct 2024

Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning

in Inflammation

Chenghui Cao
Wenwu Liu
Xin Guo
Shuwei Weng
Yang Chen
Yonghong Luo
Shuai Wang
Botao Zhu
Yuxuan Liu
Daoquan Peng

Frontiers in Immunology

doi 10.3389/fimmu.2024.1460431

11,202 views
12 citations

Perspective

Published on 23 Jan 2026

MASH and the race for liver antifibrotics

in Hepatology

Quin Wills

Frontiers in Gastroenterology

doi 10.3389/fgstr.2025.1704078

1,360 views

Original Research

Published on 23 Feb 2021

The Heat Shock Protein 40-Type Chaperone MASH Supports the Endoplasmic Reticulum-Associated Degradation E3 Ubiquitin Ligase MAKIBISHI1 in Medicago truncatula

in Plant Physiology

Marie-Laure Erffelinck
Bianca Ribeiro
Lore Gryffroy
Avanish Rai
Jacob Pollier
Alain Goossens

Frontiers in Plant Science

doi 10.3389/fpls.2021.639625

5,841 views
3 citations

Original Research

Published on 29 Sep 2025

Coptidis rhizoma ameliorates type 2 diabetes mellitus-related metabolic dysfunction-associated steatohepatitis by downregulating the IL-17RA/NF-κB signaling pathway

in Ethnopharmacology

Ning Yao
Xin Wang
Yajie Chen
Yunjuan Wu
Ying Su
Xinxin Su
Yajuan Geng
Xiaoning Liu
Limin Tian

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1667937

2,057 views

Review

Published on 16 Jul 2024

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases

in Molecular and Cellular Pathology

Reddemma Sandireddy
Suganya Sakthivel
Priyanka Gupta
Jatin Behari
Madhulika Tripathi
Brijesh Kumar Singh

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2024.1433857

53,653 views
121 citations

Original Research

Published on 23 Sep 2024

Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis

in Inflammation

Jung Hoon Cha
Na Ri Park
Sung Woo Cho
Heechul Nam
Hyun Yang
Eun Sun Jung
Jeong Won Jang
Jong Young Choi
Seung Kew Yoon
Pil Soo Sung

Frontiers in Immunology

doi 10.3389/fimmu.2024.1444100

6,205 views
4 citations

Original Research

Published on 03 Nov 2025

Multi-omics analysis elucidates the therapeutic mechanisms of the Quzhi formula in metabolic dysfunction-associated steatohepatitis targeting gut microbiota, lipid metabolism, and the role of its metabolite fraxin

in Ethnopharmacology

Jiao-Xiang Wu
Yue-Lan Wu
Mei-Fang Li
Nian Liu
Ying Liu
Yan-Ping Huang
Yuan Gan
Xiao-Yu Wang
Hai-Sheng Chai
Jin Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1694242

1,469 views

Review

Published on 20 Sep 2024

The multifaceted roles of B lymphocytes in metabolic dysfunction–associated steatotic liver disease

in Immunological Tolerance and Regulation

Huige Li
Ning Xia

Frontiers in Immunology

doi 10.3389/fimmu.2024.1447391

8,271 views
12 citations

Review

Published on 17 Jan 2024

From MASH to HCC: the role of Gas6/TAM receptors

in Inflammation

Daria Apostolo
Luciana L. Ferreira
Federica Vincenzi
Nicole Vercellino
Rosalba Minisini
Federico Latini
Barbara Ferrari
Michela E. Burlone
Mario Pirisi
Mattia Bellan

Frontiers in Immunology

doi 10.3389/fimmu.2024.1332818

11,518 views
15 citations

Review

Published on 19 Jun 2024

Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis

in Cellular Endocrinology

Bruno Ramos-Molina
Joana Rossell
Alejandra Pérez-Montes de Oca
Eva Pardina
Idoia Genua
Marina I. Rojo-López
María Teresa Julián
Núria Alonso
Josep Julve
Didac Mauricio

Frontiers in Endocrinology

doi 10.3389/fendo.2024.1400961

8,321 views
16 citations

Systematic Review

Published on 08 Oct 2025

Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis

in Cardiovascular Endocrinology

Meng Li
Jianli Hu
Yip Han Chin
Han Shi Jocelyn Chew
Wenru Wang

Frontiers in Endocrinology

doi 10.3389/fendo.2025.1681965

4,796 views
1 citation

Original Research

Published on 12 Jan 2026

Development of an in vitro metabolic dysfunction-associated steatohepatitis model to investigate altered drug metabolizing enzymes, transport proteins, and hepatobiliary disposition

in Drug Metabolism and Transport

William A. Murphy
Sarina Kyburz
Henry Ho
Matthew Shane Loop
John K. Fallon
Jacqueline B. Tiley
Thomas Kralj
Kim L. R. Brouwer

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1664808

1,380 views

Articles

Sexual dimorphism in hepatic PPAR alpha and CYP4a12a expression is associated with reduced development of drug-induced non-alcoholic steatohepatitis in female IL-33−/− mice

EMMPRIN deficiency alleviated metabolic-associated steatohepatitis progression via regulation of the UBA52–MCT1 axis

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

Common molecular basis for MASH and hepatitis C revealed via systems biology approach

Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning

MASH and the race for liver antifibrotics

The Heat Shock Protein 40-Type Chaperone MASH Supports the Endoplasmic Reticulum-Associated Degradation E3 Ubiquitin Ligase MAKIBISHI1 in Medicago truncatula

Coptidis rhizoma ameliorates type 2 diabetes mellitus-related metabolic dysfunction-associated steatohepatitis by downregulating the IL-17RA/NF-κB signaling pathway

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases

Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis

Multi-omics analysis elucidates the therapeutic mechanisms of the Quzhi formula in metabolic dysfunction-associated steatohepatitis targeting gut microbiota, lipid metabolism, and the role of its metabolite fraxin

The multifaceted roles of B lymphocytes in metabolic dysfunction–associated steatotic liver disease

From MASH to HCC: the role of Gas6/TAM receptors

Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis

Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis

Development of an in vitro metabolic dysfunction-associated steatohepatitis model to investigate altered drug metabolizing enzymes, transport proteins, and hepatobiliary disposition